Edgewise Therapeutics Inc (NASDAQ: EWTX) is -3.86% lower on its value in year-to-date trading and has touched a low of $14.90 and a high of $38.12 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EWTX stock was last observed hovering at around $25.28 in the last trading session, with the day’s gains setting it 0.39%.
Currently trading at $25.67, the stock is -2.12% and -4.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.79 million and changing 1.54% at the moment leaves the stock 2.23% off its SMA200. EWTX registered 44.86% gain for a year compared to 6-month gain of 52.34%. The firm has a 50-day simple moving average (SMA 50) of $26.7724 and a 200-day simple moving average (SMA200) of $25.10985.
The stock witnessed a -0.70% loss in the last 1 month and extending the period to 3 months gives it a -12.86%, and is -8.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.57% over the week and 8.10% over the month.
Edgewise Therapeutics Inc (EWTX) has around 110 employees, a market worth around $2.44B and $0.00M in sales. Distance from 52-week low is 72.28% and -32.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.90%).
The EPS is expected to shrink by -31.66% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Edgewise Therapeutics Inc (EWTX) Top Institutional Holders
277.0 institutions hold shares in Edgewise Therapeutics Inc (EWTX), with institutional investors hold 111.56% of the company’s shares. The shares outstanding are 94.84M, and float is at 67.23M with Short Float at 12.99%. Institutions hold 111.04% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 15.02 million shares valued at $270.54 million. The investor’s holdings represent 16.0634% of the EWTX Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 8.91 million shares valued at $160.45 million to account for 9.5269 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 6.02 million shares representing 6.8698% and valued at over $108.34 million, while NOVO HOLDINGS A/S holds 6.7844 of the shares totaling 6.34 million with a market value of $114.26 million.
Edgewise Therapeutics Inc (EWTX) Insider Activity
The most recent transaction is an insider sale by Russell Alan J, the company’s Chief Scientific Officer. SEC filings show that Russell Alan J sold 200 shares of the company’s common stock on Mar 07 ’25 at a price of $30.02 per share for a total of $6004.0. Following the sale, the insider now owns 14863.0 shares.
Edgewise Therapeutics Inc disclosed in a document filed with the SEC on Mar 07 ’25 that KOCH KEVIN (President and CEO) sold a total of 100 shares of the company’s common stock. The trade occurred on Mar 07 ’25 and was made at $30.00 per share for $3000.0. Following the transaction, the insider now directly holds 14478.0 shares of the EWTX stock.
Still, SEC filings show that on Feb 05 ’25, Russell Alan J (Chief Scientific Officer) disposed off 8,015 shares at an average price of $30.02 for $0.24 million. The insider now directly holds 14,863 shares of Edgewise Therapeutics Inc (EWTX).
